Effect of Some Antioxidants and Biochemical Parameters on Iraqi Patients Undergoing Regularly Peritoneal Dialysis
Downloads
Increased free radical species is one of the most prevalent problems in patients with chronic renal failure (CRF) receiving peritoneal dialysis (PD), which causes a variety of biochemical abnormalities, including anemia. The present research aimed at contrasting the actions of antioxidants such as superoxide dismutase (SOD), paraoxonase (PON1), and ferritin levels with oxidative stress markers such as malondialdehyde (MDA), nitric oxide (NO), and uric acid (UA), as well as levels of some biochemical variants such as blood glucose, blood urea (BU), creatinine (Cr), erythropoietin (EPO), hemoglobin (Hb), iron (Fe), and total iron binding capacity (TIBC), while body mass index (BMI) and creatinine clearance (CrCl) were calculated. The 124 participants in this study were included; 64 patients with CRF under PD, and 60 apparently healthy subjects, sex/age-matched representing the control group.
This study found a substantial drop (P < 0.05) in PON1 and SOD activity, as well as levels of Hb, Fe, TIBC, EPO, and CrCl levels in PD patients versus healthy controls. Patients showed significantly higher amounts of serum ferritin, BU, sCr, MDA, NO, UA, and BU/sCr ratio compared with controls (P < 0.05). The results showed a substantial increase (P<0.05) in the blood glucose level. Conclusion: Serum paraoxonase PON -1 activity is more typically altered than other biochemical markers in peritoneal dialysis patients. Anemia is a common and frequently early consequence of chronic kidney disorders.
1. Cohen D, Valeri AM. Treatment of irreversible renal failure. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 122.
2. American Kidney Fund. Dialysis (https://www.kidneyfund.org/treatments/dialysis).
Accessed 3/28/2025.
3. Nawal A. Murtadha and Entedhar R. Sarhat. Evaluation of apo lipoprotein A-1 and some biochemical parameters in the blood of patients with chronic kidney disease, International Journal of Advanced Chemistry Research, 2023; 5(1), PP 50-54.
4. Ying Huang1,2†, Chenling Chu2,3†, Yuanyuan Mai4, Yue Zhao1, Luxi Cao2, Shuiyu Ji2, Bin Zhu2 and Quanquan Shen. Treatment of peritoneal fibrosis: Therapeutic prospects of bioactive Agents from Astragalus membranaceu. Frontiers in Pharmacology, 2024; Vol.15, DOI 10.3389/fphar.2024.1347234.
5. Correa-Rotter R, Mehrota R, Saxena AB. Peritoneal dialysis. In: Yu ASL, Chertow GM, Luyckx VA, Marsden PA, Skorecki K, Taal MW, eds. Brenner and Rector's The Kidney. 11th ed. Philadelphia, PA: Elsevier; 2020:chap 64.
6. Chena C, Yangb L, et. al. Raman spectroscopy combined with multiple algorithms for analysis and rapid screening of chronic renal failure. Photodiagnosis and Photodynamic Therapy, 2020;30:101792.
7. Ayad Abdull-Khaleq Ismael, Abdulla Adill Raoof, Yildiz Hasan Tahseen. Assessing the accuracy of cystatin C for estimating glomerular filtration rate in patients with kidney disease. AsPac J. Mol. Biol. Biotechnol, 2024; 32 (4) : 39-45.
8. Nisansala Chandimali, Seon Gyeong Bak, Eun Hyun Park, Hyung-Jin Lim, Yeong-Seon Won, Eun-Kyung Kim, Sang-Ik Park. Free radicals and their impact on health and antioxidant defenses: a review. Cell death discovery, 2025; 11, 19.
9. Liakopoulos, V.; Roumeliotis, S.; Gorny, X.; Eleftheriadis, T.; Mertens, P.R. Oxidative Stress in Patients Undergoing Peritoneal Dialysis: A Current Review of the Literature. Oxidative Med. Cell. Longev. 2017, 2017, 3494867.
10. Subramanyam G, abdul latheef SA. Free radicals and cardiovascular diseases. Asian Journal of Clinical Cardiology. 2001; 4(1):19-26.
11. Paul S Modlinger, Christopher S Wilcox, and Shakil Aslam. Nitric oxide, oxidative stress, and progression of chronic renal failure. Seminars in Nephrology. 2004, 24(4),PP. 354-365
12. Chang BS. Ancient insights into uric acid metabolism in primates. Proceedings of the National Academy of Sciences. 2014 Mar 11;111(10):3657-8.
13. Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric acid metabolism and excretion. International journal of cardiology. 2016 Jun 15;213:8-14.
14. Peden DB, Swiersz M, Ohkubo K, Hahn B, Emery B, Kaliner MA. Nasal secretion of the ozone scavenger uric acid. American Review of Respiratory Disease. 1993 Aug 1;148:455-.
15. Dunya Abbas and Sayran Sattar Saleh. Determination of the level of homocysteine and antioxidants in the blood serum of women with gestational diabetes. Solid Statе Tеchnology. 2021, 64 (1), PP 1129 – 1135.
16. 40- Abd-Alsalam A, Zainal IG, Taqa GA. Estimation of protein oxidation parameters in patients with diabetic nephropathy. InAIP Conference Proceedings 2022 Nov 8 (Vol. 2394, No. 1). AIP Publishing.
17. Li, S. & Zhang, X. Iron in cardiovascular disease: Challenges and potentials. Front. Cardiovasc. Med. 8, 707138 (2021).
18. Alnuwaysir, R. I., Hoes, M. F., van Veldhuisen, D. J., van der Meer, P. & Grote, B. N. Iron deficiency in heart failure: Mechanisms and pathophysiology. J. Clin. Med. 2021; 11(1): 125.
19. Sotirakopoulos N, Tsitsios T, Stambolidou M, Athanasiou G, Peiou M, Kokkinou V, et al. The red blood cell deformability in patients suffering from end stage renal failure on hemodialysis or continuous ambulatory peritoneal dialysis. Ren Fail. 2004;26(2):179–83.
20. Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ. Red blood cell survival in long-term dialysis patients. Am J Kidney Dis. 2011;58(4):591–8.
21. [Canziani MEF. Complications of anemia in insufficient renal chronic. J Bras Nephrol. 2000;22(5):13-4.
22. Gokal R. Peritoneal dialysis in the 21st century: an analysis of current problems and future developments. J Am Soc Nephrol 2002;13:S104-16.
23. Saad M. Hussain Al-Obaidi, Salam S. Ahmed, Amina H. Ahmed Al-Obaidi. Evaluation of serum Chemerin level in non-diabetic, Hemodialized patients. Tikrit Journal of Pharmaceutical Sciences. 2017, 12(2),p.29.
24. Cauthen CA, Lipinski MJ, Abbate A, Appleton D, Nusca A, Varma A, Goudreau E, Cowley MJ, Vetrovec GW. Relation of blood urea nitrogen to long-term mortality in patients with heart failure. The American Journal of Cardiology. 2008 Jun 1;101(11):1643-7.
25. Jiang H, Li J, Yu K, Yang H, Min X, Chen H, Wu T. Associations of estimated glomerular filtration rate and blood urea nitrogen with incident coronary heart disease: the Dongfeng-Tongji Cohort Study. Scientific Reports. 2017 Aug 30;7(1):9987.
26. Bibi G, Green Y, Nagler RM. Compositional and Oxidative Analysis in the Saliva and Serum of Predialysis Chronic Kidney Disease Patients and End‐stage Renal Failure Patients on Peritoneal Dialysis. Therapeutic Apheresis and Dialysis. 2008 Apr;12(2):164-70.
27. Ben-Zvi I, Green Y, Nakhoul F, Kanter Y, Nagler RM. Effects of diabetes mellitus, chronic renal failure and hemodialysis on serum and salivary antioxidant status. Nephron Clinical Practice. 2007 Feb 1;105(3):c114-20.
28. González-Hernández JM, Franco L, Colomer-Poveda D, Martinez-Subiela S, Cugat R, Cerón JJ, Márquez G, Martínez-Aranda LM, Jimenez-Reyes P, Tvarijonaviciute A. Influence of sampling conditions, salivary flow, and total protein content in uric acid measurements in saliva. Antioxidants. 2019 Sep 11;8(9):389.
29. Dundar ZD, Kucukceran K, Ayranci MK. Blood urea nitrogen to albumin ratio is a predictor of in-hospital mortality in older emergency department patients. The American Journal of Emergency Medicine. 2021 Aug 1;46:349-54.
30. Gyurászová M, Gurecká R, Bábíčková J, Tóthová Ľ. Oxidative stress in the pathophysiology of kidney disease: Implications for noninvasive monitoring and identification of biomarkers. Oxidative Medicine and Cellular Longevity. 2020 Jan 23;2020.
31. Pallos D, Leão MV, Togeiro FC, Alegre L, Ricardo LH, Perozini C, Ruivo GF. Salivary markers in patients with chronic renal failure. Archives of Oral Biology. 2015 Dec 1;60(12):1784-8.
32. Rezaei F, Mohhamadi R. Comparison of saliva nitric oxide between chronic kidney disease before and after dialysis and with control group. The Open Dentistry Journal. 2018;12:213.
33. Vucijak-Grgurevic M, Zvizdic F, Durak-Nalbantic A, Jahic E, Resic N, Huskic J. Significance of nitric oxyde saliva concentration of the patients with renal failure on hemodialysis. Materia Socio-medica. 2018 Dec;30(4):246.
34. Zarbock A, Gomez H, Kellum JA. Sepsis-induced AKI revisited: pathophysiology, prevention and future therapies. Current Opinion in Critical Care. 2014 Dec;20(6):588.
35. Samouilidou, Elisabeth C., et al. "The importance of paraoxonase 1 activity in chronic kidney disease." Renal Failure 46.2 (2024): 2376930.
36. De Vecchi, Amedeo F., et al. "Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients." Nephrology Dialysis Transplantation 24.8 (2009): 2524-2529.
37. Li, Philip Kam Tao, et al. "Anemia management in peritoneal dialysis: perspectives from the Asia Pacific region." Kidney medicine 3.3 (2021): 405-411.
38. Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M. Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan. J Am Soc Nephrol. 2020;31(7):1628-1639.
39. Noori N, Murtadha N. Uncontrolled type 2 diabetes mellitus modulated plasma levels of lipid catabolic proteins. Georgian medical news. 2024(352-353):229-33.
40. Akizawa T, Nangaku M, Yonekawa T, et al. Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial. Clin J Am Soc Nephrol. 2020;15(8):1155-1165.
